<DOC>
	<DOCNO>NCT01429038</DOCNO>
	<brief_summary>The immune system patient attack liver kidney receive donor ( organ rejection ) . This prevented treating patient long-life immunosuppressive drug . Unfortunately , drug lead numerous side effect fail prevent rejection occur month later transplantation ( chronic rejection ) . Recently , show particular type cell present bone marrow , namely Mesenchymal Stem Cells ( MSC ) , injected patient , suppress immune system increase success rate blood cell transplantation . This outcome open door investigate potential cell provide valuable tool improve solid organ transplantation without need high concentration immunosuppressive drug . The present project aim evaluate safety tolerability MSC administration liver kidney transplantation .</brief_summary>
	<brief_title>Mesenchymal Stem Cells After Renal Liver Transplantation</brief_title>
	<detailed_description>The present project aim evaluate safety tolerability third party MSC administration liver kidney organ transplantation . Ten patient undergo liver transplantation 10 patient undergoing kidney transplantation include experimental arm receive single infusion MSC . The outcome 2 subgroup compare similar control patient undergo liver kidney transplantation receive MSC . Liver kidney transplant patient receive standard immunosuppressive therapy , TAC-MMF-steroïds TAC-MMF-steroïds plus IL-2-R antibody respectively . Patients enrol experimental arm infuse single dose 1,5-3,0 10E6 MSC/kg , 3 ( +/-2 ) day transplantation . Weaning immunosuppression attempt month 6 liver transplant patient present rejection episode show normal graft function graft biopsy . Kidney transplant patient continue standard immunosuppressive therapy indefinitely . Male female ( &gt; 18 year ) individual unrelated recipient graft donor MSC donor . MSC donor need fulfill generally accept criterion allogeneic HSC donation .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Male female patient 18 75 year age , undergo first Kidney Transplantation whole Liver Transplantation cadaveric donation cardiac death ( DCD ) organ donor ; Fertile female patient must use reliable contraception method ; Informed consent give patient his/next kin patient unable give inform consent , complete ( MSC + followup ) partial ( MSC + followup ) study ; Successful liver/kidney transplantation , demonstration organ function ( improvement INR liver recipient creatinine kidney recipient 2436h ) normal graft vasculature Doppler examination . Past history malignant disease , exception hepatocarcinoma within Milan criterion Liver Transplantation patient ; Active uncontrolled infection ; HIV HCV positive ; EBVnegative ; Retransplantation ; Combined transplantation ; Living related transplantation split liver transplantation ; Autoimmune disease expect impossibility wean immunosuppression ( Liver Transplantation ) corticosteroid ( Kidney Transplantation ) ; Endotracheal intubation ; Postoperative cardiovascular instability , active hemorrhage , serious clinical complication transplantation evaluation suitability MSC infusion ; For Kidney Transplantation : panel reactive antibody ( PRA ) &gt; 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>end-stage</keyword>
	<keyword>liver disease</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>cancer</keyword>
	<keyword>fulminant hepatic failure</keyword>
	<keyword>metabolic hepatic disease</keyword>
	<keyword>congenital hepatic disease</keyword>
	<keyword>renal disease</keyword>
</DOC>